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The level of copy number alteration (CNA), termed CNA burden, in the tumor genome is associated 
with recurrence of primary prostate cancer.  Whether CNA burden is associated with prostate 
cancer survival or outcomes in other cancers is unknown.  We analyzed the CNA landscape of 
conservatively treated prostate cancer in a biopsy and transurethral resection cohort, reflecting an 
increasingly common treatment approach.  We find that CNA burden is prognostic for cancer-
specific death, independent of standard clinical prognostic factors.  More broadly, we find CNA 
burden is significantly associated with disease-free and overall survival in primary breast, 
endometrial, renal clear cell, thyroid, and colorectal cancer in TCGA cohorts.  To assess clinical 
applicability, we validated these findings in an independent pan-cancer cohort of patients whose 
tumors were sequenced using a clinically-certified next generation sequencing assay (MSK-
IMPACT), where prognostic value varied based on cancer type.  This prognostic association was 
affected by incorporating tumor purity in some cohorts. Overall, CNA burden of primary and 
metastatic tumors is a prognostic factor, potentially modulated by sample purity and measurable 
by current clinical sequencing. 
 
Significance Statement:   
Tumor genomes often show alterations in copy number throughout their genomes, with the percentage of 
the genome altered termed copy number alteration (CNA) burden.  As clinical genomic analysis of tumors 
and tumor biopsies becomes widespread, there is a growing need to understand the prognostic factors 
captured by genomic features including CNA. The present work finds that increased CNA burden in 
tumors is correlated with increased mortality.  In prostate cancer, the most common malignancy in men, 
CNA burden is associated with cancer-specific death in a cohort treated conservatively, an increasingly 
common treatment approach.  Broadening these findings to other cancer types, we find CNA burden is a 
prognostic factor in breast, endometrial, renal clear cell, thyroid, and colorectal cancer.  Notably, CNA 
burden is prognostic for death in independent cancer cohorts using a clinically approved sequencing 
assay, demonstrating the potential for incorporating CNA burden assessment into clinical prognosis. 
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Introduction 
 Somatic copy number alterations (CNAs) are nearly ubiquitous in cancer (1, 2) and alter a greater 
portion of the cancer genome than any other type of somatic genetic alteration (2).  Different cancer types 
vary in their balance of copy number alterations to somatic point mutations, with prostate cancer having 
relatively high rates of CNA compared to point mutation.  Given the prevalence of CNAs in cancer, 
significant effort has been directed towards identifying specific CNAs associated with cancer clinical 
characteristics and prognosis as well as the potential driver genes they contain (3-5).  There are well 
demonstrated associations between specific CNAs and CNA signatures to cancer state and characteristics 
(6-8).  CNV patterns or clusters have been associated with high Gleason prostate cancer (Gleason 8+ 
compared to Gleason 6-7 (7)) and recurrent disease (compared to primary (6, 9, 10)).  Nonetheless, most 
CNAs are large, (1, 11) and their associations with cancer outcome may not be well identified by gene-
specific approaches.  Increasing evidence indicates that large CNAs harbor multiple drivers (12, 13), 
emphasizing the need to study their biological and clinical significance beyond individual gene-focused 
standpoints.  
 The CNA burden of a tumor is the degree to which a tumor's genome is altered as a percentage of 
genome length and represents a fundamental measure of genome copy number alteration level.  As such, 
tumor CNA burden, rather than individual CNAs, may be associated with cancer outcomes.  While tumor 
mutational burden (TMB) predicts response to immunotherapy across multiple cancer types (14, 15), 
tumor CNA burden may be prognostic for outcomes such as recurrence and survival.  Indeed, we and 
others have previously found CNA burden and genome-wide CNA patterns to be associated with 
biochemical recurrence and metastasis in primary prostate cancer, the most common cancer in men, 
across multiple cohorts (8, 16, 17).  This prognostic significance of tumor CNA burden extends to low 
and intermediate risk prostate cancer (Gleason scores of 7 and less) (16) and has the potential to better 
stratify risk in patients who are considering conservative treatment approaches such as active surveillance 
to reduce overtreatment (18, 19).   
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 In addition to questions about the prognostic potential and overall landscape of CNA in 
conservatively treated prostate cancer, it is unknown whether CNA burden is prognostic for prostate 
cancer survival, rather than only recurrence and metastasis.  Nor is it known whether the prognostic 
significance of tumor CNA burden extends to other cancer types.  Here we set out to address these 
questions, as well as whether tumor CNA burden can be prognostic in a clinical practice setting, including 
(i) in cancers treated conservatively rather than through immediate surgery or radiation, (ii) in biopsy or 
resection samples, and (iii) using a clinical targeted sequencing that allows rapid and cost-effective 
measurement of tumor CNA burden.   
To address these questions, we first examine the genomic CNA landscape of conservatively 
treated prostate cancer in more than a hundred diagnostic biopsy and resection specimens from a 
conservatively treated cohort; this cohort consisted of patients with localized prostate who were not 
treated with surgery or radiation within six months of diagnosis.  We demonstrate that tumor CNA burden 
is associated with cancer-specific death, independent of standard clinical predictors.  To explore the 
prognostic significance of tumor CNA burden more broadly in other cancer types, we find that tumor 
CNA burden is also associated with disease-free and overall survival in TCGA cohorts of primary breast, 
endometrial, renal clear cell, thyroid, and colorectal cancer in addition to prostate cancer, with the degree 
of association varying in some cancer types.  We then establish the clinical feasibility of measuring tumor 
CNA burden using the FDA-cleared MSK-IMPACT clinical next generation sequencing (NGS) assay and 
confirm that tumor CNA burden is associated with overall and disease-specific survival in both primary 
and metastatic tumors across cancer types.  In all, we demonstrate that tumor CNA burden is a prognostic 
factor associated with cancer recurrence and death in multiple cancer types, including in conservatively 
treated prostate cancer which would benefit from increased risk stratification. 
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Results 
The genomic copy number landscape of conservatively treated prostate cancer 
 To explore the genomic copy number landscape of conservatively treated prostate cancer, we set 
out to analyze copy number alteration (CNA) in cancer obtained non-surgically through biopsy and 
transurethral prostate resection (TURP) using a widely studied, conservatively treated primary prostate 
cancer cohort (20).  This retrospective Transatlantic Prostate Group 1 (TAPG1) cohort (n=1675) consists 
of men below age 76 with clinically localized prostate cancer and prostate-specific antigen (PSA) below 
100 ng/ml who did not receive surgery or radiation within 6 months of diagnosis (20).  This population-
based cohort was drawn from six cancer registries in Great Britain, and the majority of the cohort was 
followed without treatment, while a subset received hormonal therapy.  The original diagnostic samples, 
either biopsy or TURP, were obtained and centrally reviewed to obtain consistent pathological evaluation 
to the current standards.  Drawing from this cohort, we carried out genome-wide CNA analysis by array-
based comparative genomic hybridization (aCGH) of 107 biopsies or TURP samples from the TAPG1 
cohort, as tissue availability is limited for much of the full cohort.  The subset of cases used for CNA 
analysis, which make up our conservative treatment CNA cohort, have similar clinical characteristics to 
the full TAPG1 cohort, including median diagnosis age, baseline PSA, hormonal treatment, and clinical 
stage, with the exception of higher Gleason score distribution, likely due to selection for cases with 
sufficient DNA for analysis (Suppl. Table 1).  As expected for a cohort not subject to PSA screening, the 
patients are older and have higher grade at diagnosis than is typical for contemporary US cohorts.  Among 
the cohort, 47 patients developed metastasis and 43 died of prostate cancer. The median follow-up time 
for survivors was 10.3 years from diagnosis. 
 The copy number alteration landscape of the conservative treatment cohort revealed canonical 
copy number alterations of prostate cancer, including gain of chromosome 8q and losses on chromosomes 
6p, 8p, 13q and 16p, though with lower frequency than seen in prostate cancer cohorts analyzed by our 
group (MSKCC cohort) (8) and TCGA (9) (Figure 1a).  The percentage of the cancer genome showing 
copy number changes, termed tumor CNA burden (TCB), is similar between the conservative treatment 
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CNA cohort and other cohorts (Figure 1b), with a mean tumor CNA burden of 5.7% (median 1.5%, IQR 
0.05%-8.5%) compared to 5.2% (median 3.0%, IQR 0.04%-6.9%) for the 2010 MSKCC primary prostate 
cancer cohort (8) and 4.0% (median 0.7%, IQR 0.08%-5.1%) for the 2014 MSKCC primary prostate 
cancer cohort (16).  The tumor CNA burden of the conservative treatment CNA cohort is, however, 
somewhat lower than the 8.7% average tumor CNA burden of the TCGA prostate cohort (9) (mean 8.7%, 
median 6.2%, IQR 1.7%-11.9%). 
 
Tumor CNA burden is prognostic for prostate cancer-specific death 
Since tumor CNA burden is associated with prostate cancer recurrence and metastasis in 
prostatectomy cohorts (8, 16), we sought to determine whether tumor CNA burden was prognostic for 
cancer-specific death in biopsies of conservatively treated prostate cancer.  In our conservative treatment 
CNA cohort, we find that tumor CNA burden as a continuous variable is significantly associated with 
prostate cancer-specific death (per 5% tumor CNA burden, HR 1.49; 95% CI 1.30, 1.70; p <0.0001; Table 
1).  Greater tumor CNA burden correlates with an increase in death from disease compared to a lower 
tumor CNA burden (Figure 2a).  The risk of death due to prostate cancer within 5 years of diagnosis 
increases with tumor CNA burden over the majority of the tumor CNA burden distribution (Figure 2b).   
For example, the 5-year risk of death due to prostate cancer would be 13% for patients with a 2% tumor 
CNA burden and 28% for patients with a 10% tumor CNA burden (Figure 2b).  Tumor CNA burden may 
therefore serve as a prognostic factor for cancer-specific death in patients who undergo increasingly 
common conservative treatment approaches. 
 We next asked whether tumor CNA burden was associated with outcome after adjusting for 
established prognostic variables, including Gleason sum score and the UCSF Cancer of the Prostate Risk 
Assessment (CAPRA) score (21, 22) which combines PSA, Gleason score, percentage positive biopsy 
cores, clinical stage, and age (Figure 2c).  Tumor CNA burden is significantly associated with cancer-
specific death even after adjusting for biopsy Gleason score (per 5% tumor CNA burden, HR 1.44; 95% 
CI 1.24, 1.67; p <0.0001) or CAPRA score (per 5% tumor CNA burden, HR 1.44; 95% CI 1.24, 1.68; p 
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<0.0001) (Table 1, Figure 2c).  The addition of tumor CNA burden into the model with the CAPRA score 
increased Harrell’s concordance index from 0.756 to 0.805 for cancer-specific survival in our cohort of 
men with conservatively treated prostate cancer. 
 
Tumor CNA burden is prognostic for cancer-free and overall survival in multiple cancer types  
Large, clinically annotated cancer genomic efforts such as TCGA now provide an opportunity to 
examine whether CNA burden is prognostic for primary cancer outcomes across many cancer types.   In 
the TCGA primary prostate cancer cohort (9), tumor CNA burden is significantly associated with 
biochemical recurrence individually (p < 0.0001; per 5% tumor CNA burden, HR = 1.27; 95% CI, 1.13, 
1.42) and after adjustment for Gleason score and mutation burden (p = 0.015;  per 5% tumor CNA 
burden, HR = 1.18; 95% CI, 1.03, 1.35), validating our findings from other prostate cancer cohorts 
(Figure 2c, Table 2, Suppl. Fig. 1).  There were insufficient deaths in this cohort to analyze survival.  
CNA burden was still significantly associated with biochemical recurrence after adjusting for tumor 
sample purity determined by ABSOLUTE (p < 0.003; per 5% CNA burden, HR = 1.22; 95% CI, 1.07, 
1.40; Table 2).  Since tumor CNA burden could potentially reflect simply the prognostic significance of 
aneuploidy as determined by cytometric DNA index in various cancers (23, 24), we examined the tumor 
CNA burden in a multivariable model together with ploidy.  Ploidy, generated by CLONET and 
previously published for this cohort, estimates the average DNA index of the tumor cells (25, 26).  Tumor 
CNA burden was associated with recurrence independent of tumor ploidy (p = 0.002; per 5% tumor CNA 
burden, HR = 1.32; 95% CI 1.11, 1.56; Table 2).  Moreover, for a multivariable model that includes 
tumor CNA burden, Gleason grade, and mutation burden, the Harrell’s C-index is 0.691.  In contrast, the 
C-index for a model including ploidy instead of tumor CNA burden is only 0.606, indicating that a model 
with clinical factors and ploidy does not perform as well as a model with the same clinical factors and 
tumor CNA burden. 
The prognostic significance of tumor CNA burden in prostate cancer led us to ask whether tumor 
CNA burden is prognostic in other cancer types.  Towards this end, we examined published TCGA 
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cohorts for multiple cancer types with available disease-free survival and overall survival data, including 
breast (27), endometrial (28), renal clear cell (29), thyroid (30), and colorectal (31) cancers. We found 
that tumor CNA burden is associated with recurrence (disease-free survival) in these cancer types (Figure 
2c, Table 2, Suppl. Fig. 2).  This association between tumor CNA burden and lower disease-free survival 
was independent of disease stage in all cancer types except colorectal cancer, where the association was 
independent of tumor stage but not disease stage (Table 2).  In addition to lower disease-free survival, 
higher tumor CNA burden was also significantly associated with lower overall survival in breast, 
endometrial, thyroid, and colorectal cancer (Table 2).  This association with overall survival was 
independent of disease stage in breast and endometrial cancer and independent of tumor stage in 
colorectal cancer (Table 2).  There were insufficient cases of thyroid cancer with stage data for this 
analysis.  In summary, tumor CNA burden is prognostic for recurrence and/or overall survival in multiple 
cancer types beyond prostate cancer, including breast, endometrial, colorectal, renal clear cell, and thyroid 
cancer. 
 
Tumor CNA burden determined by clinical targeted sequencing of primary and metastatic tumors is 
prognostic for survival 
 We next wanted to determine whether CNA burden’s prognostic associations could be observed 
using panel-based targeted sequencing assays that are increasingly entering clinical use, in contrast to 
CGH array-based determination of tumor CNA burden.  The Memorial Sloan Kettering-Integrated 
Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) assay is a clinical laboratory 
improvement amendments (CLIA)-certified sequencing-based assay (32) of several hundred cancer genes  
and 1042 common single nucleotide polymorphisms (SNPs) that has been used to profile 504 prostate 
tumors (33) and more than ten thousand tumors across other cancer types (34).  The IMPACT assay 
identifies both somatic point mutations and copy number alterations in the genes included in the panel.  
Overall copy number burden is calculated across the whole genome (Figure 1a) using segmentation 
derived from a combination of the profiled SNPs to provide low resolution copy number data and the 
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genes sequenced in the panel (32-34).  To address the possibility that CNA burden from the IMPACT 
panel might differ from that derived from more comprehensive sequencing, we directly compared CNA 
burden calculations from 1005 tumors that were profiled using both IMPACT and whole exome 
sequencing.  CNA burden determined by the two methods were highly correlated (p-value < 0.0001, rho = 
0.88, n = 1005), indicating that CNA burden is not significantly affected by the reduced resolution in 
moving from whole exome to targeted panel sequencing (Suppl. Fig. 3).  
We find that tumor CNA burden assayed by targeted clinical sequencing is significantly 
associated with overall survival in primary prostate tumors (per 5% tumor CNA burden, HR = 1.17; 95% 
CI, 1.04, 1.3; p = 0.007; Table 3, Figure 2c, Suppl. Fig. 4) in the IMPACT prostate cohort (33).  As 
clinical sequencing assays such as MSK-IMPACT are principally used in the metastatic patient 
population, the IMPACT cohorts also provide an opportunity to investigate the prognostic significance of 
tumor CNA burden in late stage disease.  We find that tumor CNA burden of metastatic prostate tumors 
assayed by clinical sequencing is also significantly associated with survival (per 5% tumor CNA burden, 
HR = 1.07; 95% CI, 1.01, 1.14; p = 0.020; Table 3, Figure 2c, Suppl. Fig. 4).   
Since clinical sequencing assays also provide point mutation information for several hundred 
cancer genes, we asked if tumor CNA burden is prognostic after adjusting for known prostate cancer 
driver alterations.  In separate multivariable regression models adjusting for TP53, RB1, or PTEN loss 
and/or mutation, tumor CNA burden is still associated with overall survival independent of these 
alterations in primary prostate tumors (Table 3).  In metastatic tumors, these specific gene mutations do 
not reach prognostic significance when combined with tumor CNA burden (Table 3).  Notably, tumor 
CNA burden remains significant in metastatic tumors after adjusting for overall tumor mutation burden 
(per 5% tumor CNA burden, HR = 1.08; 95% CI = 1.02, 1.15; p = 0.011; Table 3). 
As targeted clinical sequencing is applied to a wide range of cancer types, we expanded our 
survival analysis to a pan-cancer cohort, consisting of 6610 primary tumors and 4864 metastatic tumors 
across 53 cancer types assayed by MSK-IMPACT sequencing panel (Methods and Suppl. Table 2).  We 
find that tumor CNA burden is prognostic for overall survival pan-cancer in primary tumors (p < 0.0001; 
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per 5% tumor CNA burden, HR = 1.04; 95% CI, 1.02, 1.05) and in metastatic tumors (p = 0.005; per 5% 
tumor CNA burden, HR = 1.02; 95% CI, 1.01, 1.03) in a univariate analysis of these pan-cancer cohorts 
(Table 3, Figure 2c).  Tumor CNA burden is also prognostic for cancer-specific death in the metastatic 
tumor cohort (p = 0.026; per 5% tumor CNA burden, HR = 1.05; 95% CI, 1.01, 1.10).  Adjustment for 
sample tumor purity determined by FACETS (35) found that CNA burden was still significantly 
associated with overall survival in primary tumors in the pan-cancer analysis approached significance for 
metastatic tumors (p = 0.06; Suppl. Table 3), though purity-adjusted CNA burden was no longer 
significantly associated with overall survival in the prostate tumor subsets (Suppl. Table 3).  Tumor 
mutation burden (TMB), in contrast to tumor CNA burden, was not associated with overall survival or 
cancer-specific survival (p = 0.4 and p > 0.9, respectively; Table 3).   
Since the pan-cancer prognostic significance of tumor CNA burden is likely to be influenced by 
the distribution of cancer types within the IMPACT cohorts, we stratified the primary and metastatic pan-
cancer IMPACT cohorts by their ten most prevalent cancer types, which make up nearly three-quarters of 
the cohort (Suppl. Table 2).  A multivariable Cox model was used for each cancer type to adjust for 
mutation burden and extract the effect size, which was then entered into a meta-analysis.  After stratifying 
by cancer type, the CNA burden of primary tumors measured by the MSK-IMPACT assay is still 
significantly associated with death (overall fixed effects HR = 1.04; 95% CI 1.02, 1.05; test of effects size 
p <0.0001; Table 3; Figure 2c).  Similarly, metastatic tumor CNA burden was associated with death 
(overall fixed effects HR = 1.02; 95% CI 1.01, 1.04; test of effects size p = 0.005; Table 3; Figure 2c).    
A closer look at the pan-cancer analysis reveals statistically significant heterogeneity in the 
relationship between tumor CNA burden and survival across tumor types (p = 0.003 and p = 0.024 in 
primary and metastatic tumor cohorts respectively, Suppl. Fig 4).  In primary tumors, heterogeneity 
appears to be driven by colorectal and pancreatic cancers, where an inverse association between tumor 
CNA burden and death is seen (Suppl. Fig. 5a).  After excluding colorectal and pancreatic cancers, 
heterogeneity is no longer statistically significant (overall fixed effects HR = 1.05; 95% CI 1.03, 1.07; test 
of effects size p <0.0001; test for heterogeneity p = 0.3; Suppl. Fig. 5a).  In metastatic tumors, two 
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outlying cancer types drive this heterogeneity: pancreatic cancer, which shows the same inverse 
association of tumor CNA burden with death as in primary pancreatic tumors, and prostate, which shows 
the opposite effect (Suppl. Fig. 5b).  Exclusion of either cancer type eliminates the significant 
heterogeneity in effects size, such that higher tumor CNA burden is associated with increased death in the 
remaining homogenous set of cancer types (overall fixed effects HR = 1.03; 95% CI 1.01, 1.04; test of 
effects size p = 0.002; test for heterogeneity p = 0.8, Suppl. Fig. 5b).  These results indicate that tumor 
CNA burden can have differing levels of prognostic effect depending on the cancer type, while a core set 
of cancer types show a statistically similar association between overall survival and tumor CNA burden 
assayed by targeted sequencing.  More generally, we find that tumor CNA burden determined by a 
clinically-certified sequencing panel is associated with overall and disease-specific mortality in a large 
multi-cancer population, including in patients with metastatic cancer where clinical sequencing is 
increasingly applied. 
 
 
Discussion 
 Many specific genes altered by CNA have been associated with cancer outcomes (3-5), however 
the relationship between outcome and the overall level of CNA harbored by a tumor is less well studied.   
Here we expanded on our previous work showing that tumor CNA burden is associated with recurrence in 
surgically treated primary prostate cancer (8, 16) by showing a significant association with death from 
prostate cancer, including in conservatively treated patients where the tumor CNA burden measurement 
was made from biopsies.  Importantly, this association remains significant even after adjusting for 
Gleason score or for CAPRA score, demonstrating that CNA burden is independent of previously 
identified associations with these measures of cancer pathology or disease state.  Thus, tumor CNA 
burden assessment from prostate biopsies could have a role in deciding between surgery and surveillance 
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for men at the low end of intermediate risk.  Conversely, it may also have role in men at high risk where 
multimodal treatment may be needed.   
An unanticipated outcome of our analysis beyond prostate cancer is the prognostic role of tumor 
CNA burden across a range of tumor types.  The pan-cancer tumor CNA burden association is significant 
but also heterogeneous depending on cancer type.  Recent work has similarly found that the presence of 
any CNA, regardless of gene identity, is associated with overall and event-free survival in pediatric AML 
(36) and that the percentage of subclonal CNAs but not subclonal somatic point mutations is associated 
with overall survival in non-small cell lung cancer (37).  Moreover, survival time was associated with a 
CNA signature derived from supervised analyses in prostate cancer and extended to breast and lung 
cancer (38).  Prognostic individual CNAs or sets of CNAs, as opposed to the broader measure of genome-
wide CNA level examined here may be specific to individual cancer types, whereas we have 
demonstrated the prognostic potential of a generalized measure of overall copy number dysregulation.  
Further work will be needed to address the trade-offs between generalizability of CNA burden and 
discriminatory power.   In addition, it will be important to investigate whether the prognostic associations 
of CNA burden from the pan-cancer analysis are independent of known cancer- or subtype-specific 
prognostic factors, such as ER receptor status in breast cancer, ultra- and hypermutated (POLE and MSI+) 
status in endometrial cancer and MSI-positive/CIN-negative status in colorectal cancer (23). 
We find it notable that tumor CNA burden assessment using a targeted sequencing can serve as a 
surrogate for tumor CNA burden calculated using more comprehensive genomic assays such as array 
CGH.  With the proliferation of different clinical sequencing panels for mutation detection, it will be of 
interest to see how much resolution, depth, and coverage can be reduced and still retain the prognostic 
association of CNA burden; future work in this area will also need to incorporate the predictive clinical 
utility of the point mutation data to address the multimodal uses of clinical sequencing assays.   Another 
important variable is tumor purity.  The prognostic significance of CNA burden can be affected by sample 
tumor purity, with purity being independently associated with outcome.  The effect of purity on the 
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association between CNA burden and outcome appears complex and may be influenced by the analysis 
platform, cancer type, and outcome type.  For example, pan-cancer CNA burden from clinical sequencing 
panel remained prognostic for survival after purity adjustment in primary tumors and was just below 
significance for metastatic tumors, though the CNA burden of the prostate tumor subset assayed by 
IMPACT sequencing panel did not.  However, the CNA burden of prostate tumors assayed by SNP array 
showed continued association with recurrence after adjustment for purity.  Tumor purity alone was also 
independently associated with survival, revealing a complex interaction between these tumor features that 
will need further exploration.  As targeted sequencing moves from tumor samples to liquid biopsy in the 
form of cell-free DNA (cfDNA) (2, 39, 40), it will be important to determine whether tumor CNA burden 
determined by analysis of cfDNA has similar prognostic utility as that determined by direct analysis of 
tumor DNA.  There is already some evidence this may be possible, as the summed CNA level of the most 
highly copy number altered genes assayed from whole genome sequencing of cfDNA in twenty metastatic 
prostate cancer patients correlated with overall survival (39).  As sequencing costs continue to drop and 
computational power improves, it would be interesting to investigate low pass whole genome sequencing 
as an alternative approach for determining tumor CNA burden that provides complete genome coverage. 
Another interesting feature of the association of tumor CNA burden with outcome demonstrated 
here is that it has prognostic significance independent of tumor mutation burden (TMB).  This is 
consistent with recent work in glioblastoma, breast, lung, and ovarian cancer showing that CNA-derived 
signatures have more prognostic power than somatic point mutation-based signatures, as measured by 
concordance index (41).  Thus, tumor CNA burden could complement clinical analyses of actionable 
driver mutations using a single panel-based sequencing assay. 
The prognostic significance of tumor CNA burden raises intriguing questions regarding the 
underlying biology.  Tumor CNA burden may be a simple measure that correlates with the extent of 
oncogenic driver alterations.  Yet, we show that tumor CNA burden retains its prognostic significance 
after adjustment for a number of known oncogenic alterations in primary prostate cancer, including PTEN 
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loss associated with increased tumor CNA burden (7, 42).  In metastatic tumors, combining tumor CNA 
burden with TP53 or RB1 loss in multivariable analyses renders both slightly below conventional 
significance thresholds, raising the possibility of biological interplay between these genes (particularly 
TP53) and subsequent copy number alteration that develops during tumor evolution.  Further, the 
prognostic associations of tumor CNA burden are independent of tumor ploidy, which suggests that tumor 
CNA burden may not simply reflect aneuploidy, defined as abnormal DNA content (24).  It is also 
possible that tumor CNA burden captures prognostic information about currently unidentified driver 
alterations and/or the rate of ongoing CNA within a tumor that may generate additional driver alterations, 
including those reflecting intratumoral heterogeneity, thereby affecting outcome.  Ongoing work by 
others has begun to develop genomic methods for identifying mechanisms of somatic CNA (43) and 
identify prognostic CNA signatures and the mechanisms underlying the component CNA (44).   
Ultimately, the biology underlying the significant association of tumor CNA burden with multiple cancer 
outcomes will be a fruitful area for future investigation. 
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Methods 
aCGH copy number analysis of conservative-treatment TAPG cohort.  Of the TAPG1 cohort (20), FFPE 
prostate tumor tissue from 180 patients was macrodissected from slides.  DNA was isolated (Agilent 
FFPE DNA isolation for aCGH protocol) and quantified by picogreen-based quantification.  107 cases 
yielded greater than 500 ug DNA and were analyzed by Agilent 180K human CGH arrays (Agilent, 
4X180K G4449A arrays, per manufacturer's instructions). Copy number data from patients in the TAPG 
copy number cohort were quantified, normalized, segmented, and analyzed with RAE, as previously 
described (8, 16).  The conservative treatment TAPG copy number cohort array data was deposited in 
NCBI GEO under accession number GSE103665.  
Tumor CNA burden (tumor CNA burden) was analyzed as percent CNA burden, defined as the length of 
the genome altered by copy number alteration multiplied by 100. For regression analyses, tumor CNA 
burden was scaled as per 5 percent so that the estimates of our hazard ratios were more interpretable. All 
statistical analyses were performed using Stata 13 (StataCorp, College Station, TX). 
TAPG copy number cohort statistical analyses 
For Cox regression analyses, the primary aim was to determine whether tumor CNA burden is associated 
with cancer specific survival (CSS).  First, we assessed whether there was an association between tumor 
CNA burden and CSS by utilizing a univariate Cox model, censoring patients who did not die at the date 
of their last follow-up and patients who died of other causes at their death date.  Secondly, in order to 
assess whether there is information from tumor CNA burden over and above biopsy Gleason score, we 
utilized a multivariable Cox model, adjusting for biopsy Gleason sum categorized as ≤6, 7, and ≥8.  
Finally, to assess whether there is an association between tumor CNA burden and CSS after accounting 
for the preoperative predictors of CSS, we utilized a multivariable Cox model, adjusting for the UCSF-
CAPRA score, a preoperative risk score calculated by incorporating the patient’s age at diagnosis, PSA at 
diagnosis, primary and secondary Gleason score at biopsy and clinical tumor stage. As percent of positive 
biopsy cores was not available for the cohort, a modified CAPRA score was utilized not incorporating 
this information.  Among our cohort of 107 patients, 47 patients were missing clinical tumor stage; 
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multiple imputation was used to impute the missing values. Statistical analyses were performed utilizing 
the measured and imputed values combined across 10 imputations using Rubin’s method. Furthermore, to 
evaluate the discriminative accuracy of the model including tumor CNA burden, we calculated bootstrap 
optimism-corrected Harrell’s C-index.  It should be noted that the discrimination of the CAPRA score is 
lower in the TAPG1 conservative treatment CNA cohort than seen in some other prostate cancer cohorts, 
and this may impact the degree to which tumor CNA burden increases the concordance index.   All data 
used for these analyses are available in Supplementary Table 4. 
For illustrative purposes, we utilized competing risk methods to estimate the probability of death from 
prostate cancer in the setting of death from other causes. Cumulative incidence was shown for patients 
who died from prostate cancer, or died from other causes, stratified on tumor CNA burden in relation to 
the median tumor CNA burden among the cohort, using the stcompet command in Stata.  
Statistical analyses of IMPACT cohorts 
For analysis of the prostate cancer MSK-IMPACT cohort (33), the published cases were analyzed by Cox 
regression for association between overall survival and tumor CNA burden (Supplementary Tables 5 and 
6).  The IMPACT cases were separated into groups consisting of primary tumors or metastatic tumors, 
including loco-regional, non-resistant to treatment, and treatment resistant, though primary tumor samples 
include cases sampled after metastatic spread.  Among our primary and metastatic IMPACT prostate 
cancer cohorts, we excluded men with unknown overall survival status and unknown time until overall 
survival status, leaving us with a final cohort of 261 and 216 men, respectively.  Among these two groups 
of patients, we assessed the association between tumor CNA burden and overall survival using a 
univariate Cox model.  Multivariable Cox models were then used to determine whether the association 
between tumor CNA burden and overall survival remained after accounting for purity determined by 
FACETS (35), the overall point mutation burden, or specific somatic gene alterations (shallow or deep 
copy number loss or mutation) occurring in prostate cancer (BRCA1, BRCA2, ATM, TP53, RB1, and 
PTEN), using separate models for each alteration. As the overall point mutation burden was not available 
for all patients, 34 patients with primary prostate cancer and 11 patients with metastatic prostate cancer 
were excluded from this portion of the analysis in their respective cohorts.  
For analysis of our pan-cancer IMPACT cohort (MSK-IMPACT cohort (34) and additionally accrued 
IMPACT samples), outcome data at time of analysis, mutation burden, and fraction genome altered data 
used were derived and available in updated form the cBio Portal 
(http://www.cbioportal.org/study?id=msk_impact_2017, samples and annotation used at time of analysis 
available as Supplementary Tables 7 and 8).  A cohort of 7305 primary tumor cases across 53 different 
cancer types and a cohort 5907 metastatic tumor cases, across 47 different cancer types, were identified. 
Within the primary and metastatic disease cohorts, we excluded patients with unknown tumor CNA 
burden, overall survival status, unreported follow-up time, death or censoring immediately after 
treatment, unknown cancer type, and unknown mutation burden.  The final cohort used here therefore 
included 6610 and 4864 patients, respectively. Within both of these cohorts, univariate Cox models were 
used to determine whether CNA or mutation burden is associated with overall survival.  Reported follow-
up time was used. As it is probable that the association between tumor CNA burden and survival likely 
varies based on the particular cancer type, we focused on patients with the ten most prevalent cancer types 
in both of the respective cohorts (Supplementary Table 2, 5198 and 3886 patients with primary and 
metastatic disease respectively) and proceeded with a meta-analysis in order to stratify by cancer type. In 
particular, we utilized a multivariable Cox model, adjusting for mutation burden for each cancer type and 
extracted the effect size. The effect size for each cancer type was then entered into a meta-analysis using 
the metan command in Stata. Both fixed effects and random effects estimates were calculated. Fixed 
effects weights were calculated using inverse-variance weighting, metan weights were calculated using 
the DerSimonian and Laird method.  
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Statistical analyses of TCGA cohorts 
For analyses of TCGA cohorts, the following published cohorts were filtered for only primary, non-
neoadjuvantly treated cases and analyzed: TCGA prostate adenocarcinoma (2015)(9), breast 
carcinoma(27), uterine endometriod cancer(45), renal clear cell carcinoma(29), papillary thyroid 
carcinoma(30), and colorectal adenocarcinoma(31). The number of cases and exclusions based on 
unavailable data are detailed in Supplementary Table 9. Cox regression was used to test the association of 
tumor CNA burden as a continuous variable with (i) cancer free status and (ii) overall survival in 
univariate models and in multivariable models with disease stage.  For the TCGA colorectal cancer 
cohort, tumor stage was also used.  For the TCGA prostate adenocarcinoma cohort, multivariable Cox 
regression models that included Gleason score, mutation count, ploidy, and/or ABSOLUTE purity (25) 
originally reported with this cohort were also used.  Analyses including purity exclude 37 patients without 
absolute tumor purity measured, resulting in analysis with 243 men, 29 of whom had BCR, and a median 
followup time for survivors of 20.1 (7.0, 37.9) months. 
 
Data access.  The conservative treatment TAPG copy number cohort array data was deposited in NCBI 
GEO under accession number GSE103665 
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE103665, reviewer access token 
czwruyesnzqbbyn). 
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Tables and Figures 
 
 
Table 1. Tumor CNA burden is associated with prostate cancer-specific death in conservative 
treatment cohort independent of Gleason sum score and CAPRA score.  Cox Regression model 
assessing the association between CNA burden (per 5%) and cancer specific survival. N=107* 
 
Model HR 95% CI P-value 
 Univariate, tumor CNA burden 1.49 1.30, 1.70 <0.0001 
 Multivariable –  adjusting for Gleason sum (≤6, 7, ≥8) 1.44 1.24, 1.67 <0.0001 
 Multivariable – adjusting for UCSF-CAPRA score 
utilizing multiple imputation 
1.44 1.24, 1.68 <0.0001 
 Multivariable – adjusting for UCSF-CAPRA score 
without utilizing multiple imputation  
     * N = 60 (excludes 47 patients with unknown stage) 
1.57 1.29, 1.92 <0.0001 
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Table 2. Tumor CNA burden is associated with recurrence and overall survival independent of 
disease stage in multiple cancer types  
Cohort Model 
Disease Free Time Overall Survival 
cases HR 95% CI P cases HR 95% CI P 
Prostate 
cancer 
TCGA  
 
Tumor CNA burden, per 5% tumor CNA burden, 
univariate 
280 1.27 1.13, 1.42 <0.0001 
 
Tumor CNA burden, per 5% tumor CNA burden, 
adjusted  for Gleason grade and mutation burden 
279 1.18 1.03, 1.35 0.015 
 
 
Tumor CNA burden, per 5% tumor CNA burden, 
adjusted for purity (ABSOLUTE)*  
243 1.22 1.07, 1.40 0.003 
Insufficient events 
 
Tumor CNA burden, per 5% tumor CNA burden, 
adjusted  for ploidy 
243 1.32 1.11, 1.56 0.002 
 
  
 
Breast  
cancer 
TCGA 
Tumor CNA burden, per 5% tumor CNA burden, 
univariate 
709 1.07 1.01, 1.14 0.028 794 1.08 1.03, 1.13 0.0005 
Tumor CNA burden, per 5% tumor CNA burden, 
Multivariable, adjusted for disease stage 
695 1.07 1.00, 1.14 0.049 777 1.08 1.03, 1.13 0.002 
Endometrial 
Cancer 
TCGA 
  
Tumor CNA burden, per 5% tumor CNA burden, 
univariate 
496 1.10 1.06, 1.14 <0.0001 536 1.13 1.08, 1.17 <0.0001 
Tumor CNA burden, per 5% tumor CNA burden, 
multivariable, adjusted for disease stage 
496 1.08 1.04, 1.13 <0.0001 536 1.10 1.05, 1.15 <0.0001 
Renal clear 
cell cancer 
TCGA 
  
Tumor CNA burden, per 5% tumor CNA burden, 
univariate 
425 1.05 1.01, 1.09 0.028 525 1.02 0.98, 1.06 NS (0.4) 
Tumor CNA burden, per 5% tumor CNA burden, 
multivariable, adjusted for disease stage 
423 1.05 1.00, 1.11 0.035 522 1.01 0.97, 1.06 NS (0.7) 
Thyroid 
cancer 
TCGA 
 
Tumor CNA burden, per 5% tumor CNA burden, 
univariate 
483 1.17 1.01, 1.35 0.033 497 1.30 1.04, 1.63 0.021 
Tumor CNA burden, per 5% tumor CNA burden, 
multivariable, adjusted for disease stage 
481 1.18 1.00, 1.39 0.048 Insufficient events 
Colorectal 
cancer 
TCGA 
Tumor CNA burden, per 5% tumor CNA burden, 
univariate 
512 1.05 1.00, 1.11 0.037 587 1.06 1.01, 1.12 0.012 
Tumor CNA burden, per 5% tumor CNA burden, 
multivariable, adjusted for disease stage 
496 1.03 0.98, 1.09 NS (0.3) 567 1.03 0.97, 1.09 NS (0.3) 
  
Tumor CNA burden, per 5% tumor CNA burden, 
multivariable, adjusted for tumor stage 
511 1.06 1.01, 1.12 0.028 585 1.07 1.02, 1.13 0.009 
* Result differed with similar adjustment in IMPACT prostate cancer cohort utilizing FACETS, see Suppl. Table  
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Table 3.  Tumor CNA burden determined by clinically approved sequencing panel is associated 
with overall survival in primary and metastatic tumors 
Model 
Overall Survival 
Primary tumors Metastatic tumors 
HR 95% CI P HR 95% CI P 
Prostate Cancera, b 
    
Univariate, tumor CNA burden, per 5%  1.17 1.04, 1.31 0.007 1.07 1.01, 1.14 0.020 
Multivariable 
     Tumor CNA burden, per 5%  
     Mutation burden (per mutation) 
 
1.11 
1.22 
 
0.98, 1.26 
1.12, 1.33 
 
0.10 
<0.0001 
 
1.08 
1.05 
 
1.02, 1.15 
1.02, 1.08 
 
0.011 
0.001 
Multivariable 
     Tumor CNA burden, per 5%  
     TP53 CN loss or mutation 
 
1.17 
4.12 
1.04, 1.31 
2.02, 8.41 
0.007 
<0.0001 
 
1.06 
1.24 
 
1.00, 1.13 
0.76, 2.02 
 
NS (0.069) 
NS (0.4) 
Multivariable 
     Tumor CNA burden, per 5%  
     RB1 CN loss or mutation 
 
1.15 
3.24 
 
1.02, 1.30 
0.70, 14.98 
0.026 
NS (0.13) 
 
1.06 
1.68 
 
0.99, 1.13 
0.94, 2.99 
 
NS (0.091) 
NS (0.080) 
Multivariable 
     Tumor CNA burden, per 5%  
     PTEN CN loss or mutation 
 
1.17 
2.38 
 
1.04, 1.32 
1.03, 5.51 
 
0.008 
0.042 
 
1.07 
1.15 
 
1.01, 1.14 
0.70, 1.89 
 
0.023 
NS (0.6) 
Pan- Cancer 
  
 
   
Univariate, tumor CNA burden, per 5%c,d   1.04 1.02, 1.05 <0.0001 1.02 1.01, 1.03 0.005 
Univariate, mutation burden (per 5 units)c,d   0.98 0.97, 1.00 NS (0.072) 0.99 0.97, 1.01 NS (0.4) 
Meta-analysis, tumor CNA burden (per 5%)e 1.04 1.02, 1.05 <0.0001f 1.02 1.01, 1.04 0.005g 
Meta-analysis, tumor CNA burden (per 5%), 
excluding outlier cancer typesh 
1.05 1.03, 1.07 <0.0001i 1.03 1.01, 1.04 0.002
j 
a Prostate primary tumors: patient n=261 for all models except multivariable model with mutation burden, where n = 227; event n=33; 
median follow-up time for survivors 40 (IQR 25,81) months 
b Prostate metastatic tumors: patient n=216 for all models except multivariable model with mutation burden, where n = 205; event 
n=80; median follow-up time for survivors 59.5 (IQR 32, 129) months 
c Pan-cancer primary tumors, univariate models: patient  n=6610, event n= 1535, median follow-up time for survivors 24 (IQR 11, 
61) months 
d Pan-cancer metastatic tumors, univariate models: patient n=4864, event n=1467, median follow-up time for survivors 51 (IQR 23, 
109) months  
e Pan-cancer meta-analysis, among ten most prevalent cancer types: primary tumor patient n = 4863, metastatic tumor patient n = 
3676. Estimates are based on overall fixed effects. 
f  p-value corresponds with test of effects size. Chi-square test for heterogeneity p-value = 0.003 
g p-value corresponds with test of effects size. Chi-square test for heterogeneity p-value = 0.024 
h Exclusion of cancer types to reduce heterogeneity: primary tumor patient n = 3887, metastatic tumor patient n = 3098. Estimates 
are based on overall fixed effects. 
i Excluding pancreatic and colorectal cancer, test of effects size p-value. Chi-square test for heterogeneity p-value = 0.3 
j Excluding pancreatic and prostate cancer,  test of effects size p-value. Chi-square test for heterogeneity p-value = 0.8 
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Figure 1. Tumor copy number landscape of conservatively treated primary prostate cancer, 
compared to other primary prostate cancer cohorts.  (a) Heat map of copy number alterations in 
conservative treatment CNA cohort, as well as TCGA, MSKCC, and IMPACT primary prostate cancer 
cohorts. (b) Frequency distribution of CNA burden, as log of percentage of genome copy number altered, 
for the conservative treatment prostate cancer cohort and three other primary prostate cancer cohorts. 
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Figure 2. Tumor copy number alteration burden is associated with death from prostate cancer in 
conservatively treated patients.  (a) Cumulative Incidence of death from disease (dashed lines) and 
death from other causes (solid lines) based in cases with high CNA burden  (red lines, CNA Burden 
greater than or equal to the median CNA burden of this cohort, 1.48) or non-high CNA burden (black 
lines, CNA Burden < median).  (b) Risk for death from prostate cancer within 5 years of diagnosis.  
Univariate risk for 5-year prostate cancer-specific death, calculated by locally weighted Kaplan–Meier 
estimates (solid black line) with 95% confidence interval (dashed black lines) overlaid on the distribution 
of CNA burden (gray). (c)  Association of tumor CNA burden with available cancer outcomes in the 
conservative treatment primary prostate cancer TAPG1 cohort, TCGA primary cancer cohorts, and the 
MSK-IMPACT clinical sequencing prostate and pan-cancer cohorts of primary and metastatic tumors. 
Forest plot of hazard ratio (per 5% CNA burden) with 95% confidence interval shown for cancer-specific 
mortality (dark blue), overall mortality (light blue), and cancer recurrence (green). 
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Supplementary Tables and Figures 
 
Supplementary Table 1.  Cohort characteristics 
 
Characteristic                           
Conservative Treatment 
CNA cohort (n=107)a 
TAPG1 cohort 
(n=2333)b 
Age (years) 70 (67, 74) 70 (66, 73) 
Median follow-up time (years) among 
survivors 
10.3 (5.0, 14.1) 14.7 (13.8, 15.8) 
Patients Underwent Hormonal Treatment 30 (28%) 670 (29%) 
Baseline PSA (ng/ml) 11.0 (4.0, 28.9) 13.0 (4.8,30.4) 
CAPRA score (n=60) 5 (2, 7)  
Mortality    
   Death from prostate cancer 43 638 
   Death from other causes 43 1012 
  Alive 21 680 
Gleason Score at Biopsy   
    ≤6 39 (36%) 749 (45%) 
      7 26 (24%) 514 (31%) 
    ≥8 42 (39%) 420 (25%) 
Clinical Stage    
    T1 20 (33%) 506 (36%) 
    T2 25 (42%) 612 (44%) 
    T3 15 (25%) 269 (19%) 
Values are displayed as median (IQR) and frequency (percentage).   
a n = 60 with available clinical stage 
b n = 2170 with available baseline PSA; n = 2330 with available survival status and censoring 
date; n =1683 with available Gleason and histology; n=1387 with evaluated clinical stage 
 
 
Supplementary Table 2.  Distribution of cancer types in IMPACT cohorts  
 
Primary tumor cohort Metastatic cohort 
  Frequency Percent Frequency Percent 
Non-Small Cell Lung 1089 16.5 719 14.8 
Breast 757 11.5 937 19.3 
Colorectal 628 9.5 544 11.2 
Glioma 627 9.5 15 0.3 
Prostate 394 6.0 335 6.9 
Pancreatic 348 5.3 243 5.0 
Bladder 329 5.0 105 2.2 
Hepatobiliary 262 4.0 102 2.1 
Esophagogastric 229 3.5 97 2.0 
Renal Cell Carcinoma 220 3.3 144 3.0 
Soft Tissue Sarcoma 200 3.0 152 3.1 
Non-Hodgkin Lymphoma 175 2.6 12 0.2 
Endometrial 166 2.5 127 2.6 
Germ Cell Tumor 120 1.8 87 1.8 
Melanoma 102 1.5 324 6.7 
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Thyroid 98 1.5 124 2.5 
Ovarian 97 1.5 154 3.2 
Mesothelioma 93 1.4 13 0.3 
Head and Neck 81 1.2 100 2.1 
Gastrointestinal Stromal Tumor 72 1.1 55 1.1 
Bone 60 0.9 41 0.8 
Small Cell Lung 42 0.6 57 1.2 
Appendiceal 41 0.6 45 0.9 
Skin, Non-Melanoma 39 0.6 37 0.8 
CNS 39 0.6 1 <0.1 
Salivary Gland 37 0.6 78 1.6 
Embryonal Tumor 32 0.5 20 0.4 
Uterine Sarcoma 29 0.4 58 1.2 
Small Bowel 27 0.4 15 0.3 
Cervical 24 0.4 30 0.6 
Ampullary Carcinoma 22 0.3 10 0.2 
Gastrointestinal Neuroendocrine Tumor 20 0.3 29 0.6 
Anal 14 0.2 20 0.4 
Adrenocortical Carcinoma 12 0.2 10 0.2 
Nerve Sheath Tumor 12 0.2 2 <0.1 
Thymic Tumor 10 0.2 1 <0.1 
Sex Cord Stromal Tumor 6 0.1 8 0.2 
Miscellaneous Brain Tumor 6 0.1 0 0.0 
Hodgkin Lymphoma 6 0.1 0 0.0 
Retinoblastoma 6 0.1 0 0.0 
Miscellaneous Neuroepithelial Tumor 5 0.1 2 <0.1 
Histiocytosis 5 0.1 1 <0.1 
Vaginal 5 0.1 1 <0.1 
Wilms Tumor 4 0.1 2 <0.1 
Penile 4 0.1 2 <0.1 
Sellar Tumor 4 0.1 0 0.0 
Breast Sarcoma 3 <0.1 2 <0.1 
Leukemia 3 <0.1 1 <0.1 
Gestational Trophoblastic Disease 3 <0.1 0 0.0 
Pheochromocytoma 1 <0.1 2 <0.1 
Multiple Myeloma 1 <0.1 0 0.0 
Pineal Tumor 1 <0.1 0 0.0 
Total 6610 100 4864 100 
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Supplementary Table 3. Association between overall survival and CNA burden after adjustment 
for purity in IMPACT prostate and pan-cancer cohorts.  Purity was determined by FACETS (35).  
Model 
Overall Survival 
Primary tumors a, c Metastatic tumors b, d 
HR 95% CI P HR 95% CI P 
Prostate Cancer: Tumor CNA burden, per 
5%, adjusted for purity a, b 
1.04 0.98, 1.11 NS (0.2) 1.00 0.96, 1.05 NS (0.9) 
Pan- Cancer: Tumor CNA burden, per 5%, 
adjusted for purity c,d   
1.02 1.01, 1.03 0.002 1.01 1.00, 1.02 NS (0.061) 
a Prostate primary tumors: patient n=193; event n=28; median follow-up time for survivors 37 (IQR 25,83) months 
b Prostate metastatic tumors: patient n=201; event n=77; median follow-up time for survivors 62.5 (IQR 33, 131) months 
c, Pan-cancer primary tumors, n=4052  
d Pan-cancer metastatic tumors n=3175 
 
Supplementary Table 4.  TAPG1 conservative treatment primary prostate CNA cohort annotation. 
Available as associated file. 
Supplementary Table 5.  MSK-IMPACT primary prostate tumor cohort annotation. Available as 
associated file. 
Supplementary Table 6.  MSK-IMPACT metastatic prostate tumor cohort annotation. Available as 
associated file.  
Supplementary Table 7.  MSK-IMPACT primary pan-cancer cohort annotation.  Available as 
associated file.  
Supplementary Table 8.  MSK-IMPACT metastatic pan-cancer cohort annotation.  Available as 
associated file.  
 
Supplementary Table 9. TCGA Cohort statistics: patient exclusion, events, and follow-up  
 
 Initial 
Cohort 
Size 
Unknown 
CNA 
Burden 
Unknown 
recur-
ence 
status or 
time  
Unknown 
OS status 
or time to 
death 
Immedi- 
ately 
censored 
after 
treatment 
Final 
Cohort 
Size 
RF 
event 
n 
Median 
followup time 
for RF 
survivors and 
IQR (months) 
OS 
event 
n 
Median 
followup time 
for OS 
survivors and 
IQR (months) 
Prostate 330 0 50 N/A 0 280 32 18  (7, 36)  -- -- 
Breast 817 0 N/A 0 23 794 53 20  (12, 38) 100 20  (12, 39) 
Endometrial 547 8 N/A 2 1 536 105 30 (17, 58) 90 31  (18, 58) 
Kidney 537 9 N/A 1 2 525 124 45 (21, 64)  175 48  (23, 71) 
 
Thyroid 507 8 N/A 1 1 497 46 31 (17, 48) 16 31 (18, 50)  
Colorectal 629 13 N/A 7 22 587 117 22  (13, 34)  124 24  (14, 36) 
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Supplementary Figure 1.  Kaplan-Meier plot of biochemical recurrence in TCGA primary prostate 
cohort.  The highest quartile tumor CNA burden (above 75 percentile CNA burden, green) is compared to 
lower three quartiles (blue) with risk table showing the number of patients present at each time point.   
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Supplementary Figure 2. Tumor CNA burden in multiple cancers is associated with disease free 
survival and overall survival.  Kaplan-Meier plot of disease free survival (left) and overall survival 
(right) of TCGA cohorts of (a) endometrial cancer and (b) colorectal cancer.  The highest quartile CNA 
(above 75 percentile CNA burden, green) is compared to lower three quartiles (blue).   
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Supplementary Figure 3. Correlation between CNA burden from IMPACT targeted sequencing 
assay and whole exome sequencing (WES) of same samples, pan-cancer. The relationship between 
CNA burden determined by IMPACT targeted sequencing and WES in a subset of pan-cancer IMPACT 
cohort samples analyzed by both approaches (n = 1005) is shown (rho=0.88, p-value=0).  
 
 
Supplementary Figure 4.  Tumor CNA burden in primary prostate cancer is prognostic for overall 
survival when assayed by clinically approved sequencing panel.  Kaplan-Meier plot of overall survival 
of IMPACT primary prostate cancer cohort by CNA burden quartile in (a) primary and (b) metastatic 
tumors.  The highest quartile CNA (above 75 percentile CNA burden, green) is compared to lower three 
quartiles (blue). 
 
 
30 
 
Supplementary Figure 5. Forest Plot of Hazard Ratios (individual and pooled) for meta-analysis 
assessing the association between tumor CNA burden and overall survival in (a) primary cancer and (b) 
patients with metastatic cancer in the pan-cancer IMPACT cohort 
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